<DOC>
	<DOCNO>NCT01651143</DOCNO>
	<brief_summary>Primary Objective : - To evaluate safety tolerability 8-week oral administration SAR100842 patient diffuse cutaneous systemic sclerosis . Secondary Objectives : - To evaluate pharmacodynamic effect SAR100842 patient systemic sclerosis measure disease related biomarkers Lysophosphatidic acid ( LPA ) receptor signal marker blood skin ; - To explore effect SAR100842 skin thickness patient systemic sclerosis measure modified Rodnan Skin Score ( mRSS ) ; - To explore effect SAR100842 quality life measure Scleroderma Modified Health Assessment Questionnaire ( SHAQ ) ; - To document long term safety SAR100842 extension part .</brief_summary>
	<brief_title>Proof Biological Activity SAR100842 Systemic Sclerosis</brief_title>
	<detailed_description>Core part : randomize , double-blind , placebo-controlled study - 8-week treatment Extension part participant complete core part : Open label non-controlled study - 16-week treatment Each patient 's participation study approximately 13 33 week depend participation extension part : 2 week screen , 8 week treatment core part , 1 30 day wash-out core part extension part , 16 week treatment extension part 3 week follow .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Inclusion criterion : Patients meet American College Rheumatology ( ACR ) criteria systemic sclerosis diffuse cutaneous involvement &lt; 36 month since onset first systemic sclerosis manifestation Raynaud 's phenomenon Modified Rodnan Skin Score ( mRSS ) â‰¥ 15 area definite involvement dorsal forearm consider amenable repeat 4mm skin biopsy . Exclusion criterion : 1 . Patients high dose unstable low dose immunosuppressive drug , cytotoxic , antifibrotic glucocorticoid drug least 4 week prior screen 2 . Serum creatinine &gt; 2.0 mg/dL 3 . Gastrointestinal involvement prevent oral administration study drug 4 . Severe cardiac and/or pulmonary disease The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>